Congenica
2012
FOUNDED
PRIVATE
STATUS
31-40
EMPLOYEES
Early Stage VC
LATEST DEAL TYPE
$13M
LATEST DEAL AMOUNT
9
INVESTORS
Description
Developer of a clinical genome analysis platform designed to identify genetic diseases in patients. The company's platform processes genomic data sets to detect mutations by filtering clinically relevant variants and deep clinical phenotyping, enabling clinicians to provide actionable interpretation of genetic disease for patients.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Decision/Risk Analysis
Other Healthcare Technology Systems
Primary Office
- Wellcome Trust Genome Campus
- Hinxton
- Cambridge CB10 1DR
- England, United Kingdom
+44 01223 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Congenica’s full profile, request a free trial.
Congenica Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Early Stage VC | 26-Nov-2018 | $13M | 000.00 | Completed | Startup | |
| 6. Early Stage VC (Series B) | 27-Apr-2017 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 5. Grant | 29-Sep-2015 | 00000 | 00.000 | Completed | Generating Revenue | |
| 4. Early Stage VC (Series A) | 01-Apr-2015 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 3. Grant | 11-Mar-2015 | 00.00 | 00.000 | Completed | Startup | |
| 2. Seed Round | 05-Dec-2014 | $2.44M | $2.44M | Completed | Startup | |
| 1. Grant | 02-May-2014 | $573K | Completed | Startup |
Congenica Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| B Ordinary | 0,000,000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | ||
| A Ordinary | 0,000,000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | ||
| A Ordinary | 000,000 | 00.00 | 00.00 | 00 | 00.00 | 00 | ||
| A Ordinary | 3,996,428 | $0.63 | $0.63 | 1x | $0.63 | 20.02% | ||
| A Ordinary | 2,553,500 | $0.25 | $0.25 | 1x | $0.25 | 12.79% |
Congenica Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| BGI | VC-Backed Company | Minority | 000 0000 | 000000 0 | ||
| Future Planet Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | ||
| Healthlink Capital | Other | Minority | 000 0000 | 000000 0 | ||
| Parkwalk Advisors | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Innovate UK | Government | 000 0000 | 000000 0 |
Congenica Executive Team (16)
7 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Congenica Board Members (14)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alastair Kilgour | Parkwalk Advisors | Board Member | 000 0000 | |
| Andrew Richards | Congenica | Chairman | 000 0000 | |
| David Atkins Ph.D | Congenica | Chief Executive Officer & Board Member | 000 0000 | |
| Hermann Hauser Ph.D | Amadeus Capital Partners | Board Member | 000 0000 | |
| Matthew Hurles | Congenica | Scientific Director & Board Member | 000 0000 |
4 Former Board Members
You’re viewing 5 of 14 board members. Get the full list »